Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #Appointment #NASDAQ #Investing

King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to...


http://dlvr.it/TP0HMf

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

ASTRA TT Signs Strategic MOU with India's BIS to Accelerate Green Charging Infrastructure Across the Nation #Publishing #Technology